Results 91 to 100 of about 21,670 (174)

Protective effect of carvedilol in cardiomyopathy caused by anthracyclines in patients suffering from breast cancer and lymphoma [PDF]

open access: yes
Objective: Anthracyclines can damage the left ventricle, causing cardiomyopathy. This study evaluated the protective effect of carvedilol in cardiomyopathy caused by anthracyclines in patients suffering from breast cancer and lymphoma.
گلدوست, محمد   +5 more
core  

FORMULATION AND CHARACTERIZATION OF CARVEDILOL NANOEMULSION ORAL LIQUID DOSAGE FORM [PDF]

open access: yes, 2015
Objective: Carvedilol is antihypertensive. It is practically water insoluble. Therefore, the objective of this investigation is a formulation and characterization of carvedilol nano emulsion (NE) employing orally to increase carvedilol solubility for ...
Drais, Hayder Kadhim   +1 more
core   +1 more source

Nano and Microparticulate Chitosan Based System for Formulation of Carvedilol Rapid Melt Tablet

open access: yesAdvanced Pharmaceutical Bulletin, 2015
Purpose: In the present study rapid melt tablets (RMT’s) of carvedilol were prepared by using ionotropic-gelated chitosan nanoparticles using a spray-drying method.
Ravindra Patil   +2 more
doaj   +1 more source

Lowering hepatic venous pressure agent carvedilol versus variceal banding ligation for clinical outcomes of cirrhotic portal hypertension

open access: yes, 2018
Zhen-gang Wei,1–3 Feng-xian Wei,1–3 Zi-wei Shao,1–3 Guo-hong Su,1–3 Xue-ping Qi,3 You-cheng Zhang1–3 1Department of General Surgery, Lanzhou University Second Hospital, Lanzhou 730030, China; 2Hepato-Biliary-Pancreatic ...
Shao Z   +5 more
core  

Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats [PDF]

open access: yes, 2011
The cardiovascular effects and mechanism of antihypertensive response of carvedilol were assessed in fructose fed rats using pharmacokinetic–pharmacodynamic (PK-PD) modelling.
Chiappetta, Diego Andrés   +15 more
core   +1 more source

Post-carvedilol myocardial function in cats with obstructive hypertrophic cardiomyopathy

open access: yesFrontiers in Veterinary Science
IntroductionHypertrophic cardiomyopathy (HCM) is the most prevalent cardiac disease in cats, and one phenotype includes obstructive HCM with dynamic left ventricular outflow tract obstruction (DLVOTO). Myocardial function has been reported to be lower in
Takahiro Saito   +9 more
doaj   +1 more source

BETA-BLOCKERS AND RENOPROTECTION: THE POTENTIAL OF CARVEDILOL [PDF]

open access: yes, 2017
The review presented the importance of carvedilol using in terms of renoprotection in renal dysfunction at the pre-dialysis stage of the disease in order to reduce the risk of progression of chronic kidney diseases (CKD) and the development of ...
F. A. Yusupov   +3 more
core   +1 more source

Carvedilol for prevention of atrial fibrillation after cardiac surgery: a meta-analysis.

open access: yesPLoS ONE, 2014
BackgroundPostoperative atrial fibrillation (POAF) remains the most common complication after cardiac surgery. Current guidelines recommend β-blockers to prevent POAF. Carvedilol is a non-selective β-adrenergic blocker with anti-inflammatory, antioxidant,
Hui-Shan Wang   +2 more
doaj   +1 more source

Toxic epidermal necrolysis associated with carvedilol treatment

open access: yes, 2010
Objective: To report a case of fatal toxic epidermal necrolysis associated with carvedilol treatment. Case summary: Two days after the initiation of carvedilol treatment, a 70-year old woman presented with skin eruptions in the form of maculous rash with
Milić, Sandra   +13 more
core   +1 more source

Metal-chelating properties of carvedilol: an antihypertensive drug with antioxidant activity

open access: yes, 2009
Carvedilol (CarvH) (1-[carbazolyl-(4)-oxyl]-3-[2-methoxyphenoxyethyl)-amino]-2-propanol, an antihypertensive agent with β-blocker function, has been shown to act as an antioxidant.
Massimiliano Peana   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy